Gynecologic Oncology

Resource Center

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Commentary Podcasts Q&As Videos
Interactive
Polls Quizzes Slideshows
Events & Education

FDA Alerts

FDA Alert
FDA
FDA Alert
FDA Approves Relacorilant (Lifyorli) Plus Nab-Paclitaxel for Platinum-Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
04/13/2026
Anthony Calabro, MA
On March 25, the FDA has approved relacorilant (Lifyorli), in combination with nab-paclitaxel for adults with platinum-resistant ovarian and related gynecologic cancers who have received prior systemic...
04/13/2026